On Dec. 11, 2022, Novavax announced that the Switzerland’s Federal Office of Public Health and Francees Haute Autorite de Sante had expanded their recommendations for use of Nuvaxovid (NVX-CoV2373) as a COVID-19 booster.

In Switzerland, the FOPH recommended use of Nuvaxovid as a booster in individuals aged 16 and older for the first booster after priming or after the third dose regardless of previous vaccine history. In France, the HAS recommended Nuvaxovid as a homologous booster dose to enable people who have received a primary vaccination to receive a booster dose.